Ivax CFC-Free Albuterol Will Launch In Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cleared the NDA for the asthma treatment Oct. 29. Ivax’ CFC-free albuterol inhaler offers an alternative to GlaxoSmithKline’s Ventolin HFA in advance of an FDA final rule that is expected to remove CFC-propelled albuterol from the market in 2006.
You may also be interested in...
Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand
The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.
Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand
The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.
Ivax Breath-Activated HFA Albuterol Is “Approvable”
Ivax' breath-activated hydrofluoroalkane-propelled albuterol is "approvable" at FDA, the company announced July 7